Pardes Biosciences, Inc. (PRDS) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Carlsbad, CA, アメリカ. 現CEOは Thomas G. Wiggans.
PRDS を有する IPO日 2021-12-27, 57 名の正社員, に上場 NASDAQ Global Market, 時価総額 $135.19M.
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.
